CA2293549A1 - Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase - Google Patents

Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase Download PDF

Info

Publication number
CA2293549A1
CA2293549A1 CA002293549A CA2293549A CA2293549A1 CA 2293549 A1 CA2293549 A1 CA 2293549A1 CA 002293549 A CA002293549 A CA 002293549A CA 2293549 A CA2293549 A CA 2293549A CA 2293549 A1 CA2293549 A1 CA 2293549A1
Authority
CA
Canada
Prior art keywords
phenyl
protein transferase
farnesyl
substituted tricyclic
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002293549A
Other languages
French (fr)
Other versions
CA2293549C (en
Inventor
Adriano Afonso
Joseph M. Kelly
Jay Weinstein
Ronald L. Wolin
Stuart B. Rosenblum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293549A1 publication Critical patent/CA2293549A1/en
Application granted granted Critical
Publication of CA2293549C publication Critical patent/CA2293549C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Novel phenyl-substituted tricyclic compounds of formula (1.0) and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.
CA002293549A 1997-06-17 1998-06-15 Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase Expired - Fee Related CA2293549C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87705297A 1997-06-17 1997-06-17
US08/877,052 1997-06-17
PCT/US1998/011509 WO1998057950A1 (en) 1997-06-17 1998-06-15 Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
CA2293549A1 true CA2293549A1 (en) 1998-12-23
CA2293549C CA2293549C (en) 2008-08-05

Family

ID=25369151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293549A Expired - Fee Related CA2293549C (en) 1997-06-17 1998-06-15 Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase

Country Status (10)

Country Link
EP (1) EP0989981A1 (en)
JP (1) JP2002504150A (en)
KR (1) KR20010013945A (en)
CN (1) CN1267292A (en)
AU (1) AU8253798A (en)
CA (1) CA2293549C (en)
HU (1) HUP0003215A2 (en)
IL (1) IL133446A0 (en)
NZ (1) NZ501613A (en)
WO (1) WO1998057950A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them
ES2164717T3 (en) * 1993-10-15 2002-03-01 Schering Corp SULFONAMIDE TRICICLIC COMPOUNDS USEFUL TO INHIBIT THE FUNCTION OF G-PROTEIN AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2174105C (en) * 1993-10-15 2002-02-12 W. Robert Bishop Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NZ326035A (en) * 1995-12-22 2000-01-28 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
JP2002504150A (en) 2002-02-05
WO1998057950A1 (en) 1998-12-23
HUP0003215A2 (en) 2001-06-28
EP0989981A1 (en) 2000-04-05
CN1267292A (en) 2000-09-20
KR20010013945A (en) 2001-02-26
NZ501613A (en) 2001-11-30
AU8253798A (en) 1999-01-04
IL133446A0 (en) 2001-04-30
CA2293549C (en) 2008-08-05

Similar Documents

Publication Publication Date Title
CA2293706A1 (en) N-substituted urea inhibitors of farnesyl-protein transferase
CA2217477A1 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
CA2217499A1 (en) Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2216160A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2216163A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117782A0 (en) Tricyclic compounds
CA2217351A1 (en) Carbonyl-piperazinyl and piperidinyl compounds which inhibit farnesyl protein transferase
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
CA2183315A1 (en) Novel Mercaptoacetylamido 1,3,4,5-Tetrahydro-Benzo[c]azepin-3-One Disulfide Derivatives Useful as Inhibitors of Enkephalinase and Ace
CA2293714A1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
TR199901274T2 (en) New tricyclic piperidinyl compounds useful as farnesyl protein transferase inhibitors
CA2293358A1 (en) Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
DE69926078D1 (en) Farnesyl-protein transferase inhibitoren
IE890748L (en) Peptides with pharmaceutical activity
CA2293549A1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
AU3737097A (en) Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase
CA2293553A1 (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
CA2293713A1 (en) Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
IL89537A (en) Di- and tripeptides having inhibitory action on the enzymatic system, their preparation and pharmaceutical compositions containing them
CA2245758A1 (en) Benzo[c]quinolizine derivatives, their preparation and use as 5.alpha.-reductases inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed